Roche finally ups bid for Illumina – but will it be enough?
This article was originally published in Clinica
Executive Summary
Two months after launching its hostile takeover bid of Illumina and having made little progress, Roche has increased its offer by 15%, to $51 per share, bringing the total transaction value to $6.7bn. However, this still may not be enough for the Swiss drugs and diagnostics giant to bag the gene sequencing firm, the stock of which analysts have previously said could be worth around $60 per share.